NasdaqCM:BPTH

Stock Analysis Report

Executive Summary

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.

Risk Analysis

Earnings are forecast to decline by an average of -13.3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($37K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Bio-Path Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BPTH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.9%

BPTH

1.1%

US Biotechs

1.7%

US Market


1 Year Return

336.6%

BPTH

11.5%

US Biotechs

23.2%

US Market

Return vs Industry: BPTH exceeded the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: BPTH exceeded the US Market which returned 24.7% over the past year.


Shareholder returns

BPTHIndustryMarket
7 Day6.9%1.1%1.7%
30 Day0.5%1.7%4.2%
90 Day-30.5%21.5%11.9%
1 Year336.6%336.6%12.5%11.5%25.8%23.2%
3 Year-95.9%-95.9%29.3%25.1%52.8%42.9%
5 Year-98.4%-98.4%4.4%-0.5%75.2%55.8%

Price Volatility Vs. Market

How volatile is Bio-Path Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bio-Path Holdings undervalued compared to its fair value and its price relative to the market?

1.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BPTH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BPTH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BPTH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BPTH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BPTH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BPTH is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Bio-Path Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-13.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BPTH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BPTH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BPTH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BPTH is forecast to have no revenue next year.

High Growth Revenue: BPTH is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BPTH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bio-Path Holdings performed over the past 5 years?

-13.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BPTH is currently unprofitable.

Growing Profit Margin: BPTH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BPTH is unprofitable, and losses have increased over the past 5 years at a rate of -13.8% per year.

Accelerating Growth: Unable to compare BPTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BPTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: BPTH has a negative Return on Equity (-50.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Bio-Path Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: BPTH's short term assets ($16.9M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: BPTH's short term assets ($16.9M) exceed its long term liabilities ($352.0K).


Debt to Equity History and Analysis

Debt Level: BPTH is debt free.

Reducing Debt: BPTH has not had any debt for past 5 years.


Balance Sheet

Inventory Level: BPTH has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BPTH's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BPTH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BPTH has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 7.8% each year.


Next Steps

Dividend

What is Bio-Path Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BPTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BPTH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BPTH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BPTH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BPTH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Bio-Path Holdings's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average board tenure


CEO

Peter Nielsen (70yo)

12yrs

Tenure

US$671,927

Compensation

Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licen ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD671.93K) is about average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

3.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: BPTH's board of directors are considered experienced (3.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$171,64323 Jan 19
Armistice Capital LLC
EntityCompany
Shares64,457
Max PriceUS$2.66

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 259.5%.


Management Team

  • Doug Morris (63yo)

    Co-Founder

    • Tenure: 13yrs
    • Compensation: US$90.76k
  • Peter Nielsen (70yo)

    Co-Founder

    • Tenure: 12yrs
    • Compensation: US$671.93k
  • Alan MacKenzie

    Consultant

    • Thomas Walker

      Consultant

      • Jeffery Lancet

        Consultant

        • Victoria Lake

          Regulatory Consultant

          • Ana Ashizawa

            Senior Vice President of Research

            • Anthony Price

              Senior Vice President of Finance


              Board Members

              • Jorge Cortes

                Chairman of the Scientific Advisory Board

                • Tenure: 4.4yrs
              • Doug Morris (63yo)

                Co-Founder

                • Tenure: 13yrs
                • Compensation: US$90.76k
              • Martina Molsbergen (54yo)

                Independent Director

                • Tenure: 0.3yrs
              • Peter Nielsen (70yo)

                Co-Founder

                • Tenure: 12yrs
                • Compensation: US$671.93k
              • Anas Younes

                Member of Scientific Advisory Board

                • Tenure: 1yrs
              • Jason Fleming

                Member of Scientific Advisory Board

                • Tenure: 1.4yrs
              • Heath Cleaver (46yo)

                Independent Director

                • Tenure: 5.9yrs
                • Compensation: US$56.79k
              • D. Hooper

                Member of Scientific Advisory Board

                • Tenure: 2.9yrs

              Company Information

              Bio-Path Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


              Key Information

              • Name: Bio-Path Holdings, Inc.
              • Ticker: BPTH
              • Exchange: NasdaqCM
              • Founded: 2007
              • Industry: Biotechnology
              • Sector: Pharmaceuticals & Biotech
              • Market Cap: US$28.206m
              • Shares outstanding: 3.69m
              • Website: https://www.biopathholdings.com

              Number of Employees


              Location

              • Bio-Path Holdings, Inc.
              • 4710 Bellaire Boulevard
              • Suite 210
              • Bellaire
              • Texas
              • 77401
              • United States

              Listings

              TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
              BPTHNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2008
              IBPBDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2008

              Biography

              Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. 


              Company Analysis and Financial Data Status

              All financial data provided by Standard & Poor's Capital IQ.
              DataLast Updated (UTC time)
              Company Analysis2020/01/17 01:51
              End of Day Share Price2020/01/16 00:00
              Earnings2019/09/30
              Annual Earnings2018/12/31


              Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.